The ASCO Endorsement Panel has endorsed the Cancer Care Ontario Guideline for Active Surveillance for the Management of Localized Prostate Cancer. This evidence-based recommendation includes:

• For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy.

• Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions.

• Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance.

• Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies.

• Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings.

• Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.

Citation: Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement. [Published online ahead of print February 16, 2016]. Clin Oncol. doi:10.1200/JCO.2015.65.7759.